March 31, 2025- Abbott announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip device significantly reduced the rate of hospitalizations due to heart failure compared to medical therapy, while offering long-term quality-of-life benefits for patients.
The TRILUMINATE Pivotal trial is the first randomized, controlled clinical study to evaluate the safety and effectiveness of transcatheter repair with the TriClip system compared to medical therapy alone in people with severe TR. TriClip is approved for use in more than 50 countries, including in the U.S., Europe and Canada.